Teva Pharmaceuticals: Pricing the 2016 Bond Offering Custom Case Solution & Analysis

Evidence Brief: Teva Pharmaceuticals 2016 Bond Offering

1. Financial Metrics

• Acquisition Price: $40.5 billion total for Allergan s generic business (Actavis). Components include $33.75 billion in cash and $6.75 billion in Teva stock.
• Debt Offering Size: $20.4 billion equivalent, across multiple currencies (USD, EUR, CHF). This is one of the largest non-bank corporate debt issuances in history.
• Credit Ratings: Standard & Poor s: BBB. Moody s: Baa2. Both represent the lower end of investment grade.
• Interest Rates: 10-year US Treasury yield at approximately 1.5% in July 2016. 10-year German Bund yield in negative territory.
• Existing Debt: Teva carried approximately $10 billion in debt prior to this acquisition.
• Pro-forma Net Debt/EBITDA: Projected to rise above 4.0x immediately following the transaction.

2. Operational Facts

• Transaction Target: Actavis, the generics division of Allergan. Includes over 1,000 marketed products and a pipeline of 250+ Abbreviated New Drug Applications (ANDAs).
• Market Position: Teva remains the largest generic drug manufacturer globally. The Actavis deal consolidates this position in the US and Europe.
• Timing: July 2016, shortly after the Brexit vote, which caused significant volatility in global capital markets and a flight to quality.
• Tranche Structure: Proposed maturities ranging from 2 to 30 years to diversify the repayment schedule.

3. Stakeholder Positions

• Erez Vigodman (CEO): Committed to a strategy of growth through massive acquisition to offset the loss of exclusivity on Copaxone.
• Institutional Investors: Seeking yield in a low-interest-rate environment but concerned about the high debt load and generic pricing deflation.
• Credit Rating Agencies: Signaled that any further increase in debt or failure to integrate Actavis would lead to a downgrade to speculative grade (junk).
• Allergan: Required the cash component to fund its own strategic pivot and share buyback programs.

4. Information Gaps

• Generic Pricing Trends: The case lacks specific data on the accelerating deflation in US generic drug prices during mid-2016.
• Copaxone Revenue Decay: Precise timeline for the entry of multiple generic competitors for Teva s flagship 40mg product.
• Post-Merger Savings: Detailed breakdown of the $1.4 billion in projected annual cost reductions.

Strategic Analysis: Capital Structure Optimization

1. Core Strategic Question

• How should Teva price and structure its $20.4 billion debt offering to ensure full subscription while minimizing the long-term cost of capital?
• Can Teva maintain its investment-grade rating while absorbing a debt load that exceeds four times its annual earnings?

2. Structural Analysis

The generic pharmaceutical industry is shifting from high-margin specialty products to high-volume, low-margin commodities. Teva is using a massive acquisition to achieve economies of scale. Applying a capital structure lens, the firm is moving toward an aggressive debt-to-equity ratio at a time when its primary cash cow, Copaxone, faces imminent generic competition. The Bargaining Power of Buyers (large pharmacy benefit managers) is increasing, putting downward pressure on the margins needed to service this new debt.

3. Strategic Options

4. Preliminary Recommendation

Teva must pursue a Multi-Currency Laddering strategy with a slight premium on the long-dated USD tranches. The priority is not the lowest possible interest rate but the certainty of execution and the extension of the maturity profile. Given the Brexit-induced volatility, Teva should over-allocate to the 10-year and 30-year tranches to avoid a refinancing cliff in the early 2020s when Copaxone revenue will be at its lowest.

Operations and Implementation Planner

1. Critical Path

• Book-building (Days 1-3): Launch the roadshow across London, New York, and Boston. Gauge demand at various spread levels over Treasuries and Mid-Swaps.
• Pricing Finalization (Day 4): Set final coupons for the 20+ tranches. Prioritize the USD 10-year and 30-year notes as the anchor of the offering.
• Closing and Funding (Day 10): Transfer $33.75 billion to Allergan. Ensure immediate legal integration of Actavis assets to start capturing cash flow.
• 90-Day De-leveraging Plan: Initiate the sale of non-core assets to signal commitment to debt reduction to rating agencies.

2. Key Constraints

• Market Capacity: The sheer size of the offering ($20B+) tests the depth of the corporate bond market for a BBB-rated issuer.
• Rating Agency Sensitivity: Any deviation from the projected integration timeline will trigger a downgrade, increasing the cost of future revolvers.
• Operational Friction: Integrating two massive global supply chains while trying to cut $1.4 billion in costs often leads to stock-outs and lost market share.

3. Risk-Adjusted Implementation Strategy

The plan assumes stable interest rates during the 48-hour pricing window. To mitigate volatility, Teva should utilize interest rate swaps to lock in the underlying Treasury rates before the formal launch. Implementation success depends on the rapid appointment of a single integration lead for the US generics business, as this unit must generate the cash for the first interest payments due in early 2017. Contingency: if the 30-year tranche is under-subscribed, Teva must be prepared to increase the yield by 15-20 basis points immediately rather than risk a failed auction.

Executive Review and BLUF

1. BLUF

Proceed with the $20.4 billion bond offering immediately. The current interest rate environment is historically favorable, and the Actavis acquisition is essential for Teva to maintain its leadership in generics. However, the pricing must include a New Issue Premium to ensure the book is 2x oversubscribed. Failure to close this deal leaves Teva with an unsustainable concentration in Copaxone. Success depends on maintaining the BBB rating through aggressive post-deal asset sales and cost discipline. The focus is on liquidity and duration, not just the lowest coupon.

2. Dangerous Assumption

The analysis assumes that the generic drug market in the United States will remain stable. It ignores the structural shift toward aggressive price deflation driven by consolidated buyer power. If generic margins compress by more than 10% annually, the projected EBITDA will not support the interest payments, regardless of how well the bonds are priced today.

3. Unaddressed Risks

• Rating Downgrade (Probability: High; Consequence: Severe): If the integration stalls, a move to junk status would trigger mandatory sell-offs by institutional funds, collapsing the bond price and cutting off future capital access.
• Regulatory Intervention (Probability: Moderate; Consequence: High): Increased scrutiny on generic drug pricing by US regulators could cap the upside of the Actavis pipeline.

4. Unconsidered Alternative

The team failed to consider a smaller debt offering combined with a larger equity raise. While equity is more expensive than debt, Teva s current stock price is relatively high. Issuing an additional $5 billion in equity would have lowered the debt-to-EBITDA ratio to a safer 3.2x, providing a cushion against the inevitable decline of Copaxone and the volatility of the generics market. This would have protected the investment-grade rating more effectively than the current all-debt approach.

5. MECE Verdict

APPROVED FOR LEADERSHIP REVIEW